Roche says data in hepatitis treatment encouraging
ZURICH (Reuters) - Swiss drugmaker Roche said on Thursday initial data on a protease inhibitor, danoprevir, is encouraging against Hepatitis C.
"The high sustained viral response rates and encouraging safety data show danoprevir is potent and well-tolerated," Roche development head Hal Barron said in a statement.
"Roche's HCV portfolio includes multiple investigational drugs with different modes of action, allowing us to develop tailored treatments that aim to address the future needs of patients with chronic hepatitis C," Barron said.
(Reporting By Katharina Bart)
- Tweet this
- Share this
- Digg this
- OPEC oil output hits highest since 2012 on Libya, Saudi-Reuters Survey
- Lightning, rain fail to deter resolute Hong Kong protesters
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State
- Obama, Modi work to deepen improving U.S.-India ties
- Obama, Modi discuss trade, climate, Islamic State at White House
Children represent just 15 percent of the recorded 3,091 Ebola deaths recorded mostly in Liberia, Sierra Leone and Guinea. But that number masks the broader impact the disease is having on children. Fear of contagion means many orphans, even those who test negative, are being abandoned. Full Article